$INKT News

MiNK Therapeutics Announces First Patient Dosed In Randomized Phase 2 Clinical Trial Evaluating Agent-797 With SOC Vs Placebo With SOC In Patients With Severe Acute Lung Injury And Critical Illness

MiNK Therapeutics Presents New Clinical, Translational Data On Agent-797 Showing Pathogen Suppression, Lung Immune Restoration And Tissue Repair Activation, Supporting Ongoing Phase 2 Trial, At ATS 2026

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate

MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...

MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript

MiNK (INKT) Q4 2025 Earnings Call Transcript

MiNK Therapeutics Q1 Earnings Call Highlights

MiNK Therapeutics (NASDAQ:INKT) Posts Narrower-Than-Expected Q1 Loss, Advances iNKT Therapy Into Pivotal Testing

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

Transcript: MiNK Therapeutics Q1 2026 Earnings Conference Call

MiNK Therapeutics Q1 EPS $(0.57) Beats $(0.78) Estimate

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

MiNK Therapeutics, First Lviv Territorial Medical Union Initiate Phase 2 Clinical Study Of AgenT-797 Allogeneic Invariant Natural Killer T Cell Therapy To Treat Severe Acute Lung Injury

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

MiNK Therapeutics Presents Data Showing Agent-797, Off-The-Shelf, Allogeneic iNKT Cell Therapy Produces Fundamentally Different, Disease-Appropriate Immune Responses At ASGCT 2026

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

MiNK Therapeutics Presents Data From Investigator-Initiated Phase II Trial, Evaluating agenT-797, MiNK's allo-iNKT Cell Therapy, In Combination With BOT And BAL, Ramucirumab And Paclitaxel In PD-1 Refractory Gastroesophageal Cancer, At 2026 AACR Annual Meeting